NasdaqGS:HALOBiotechs
Halozyme GSK ENHANZE Deal Adds Oncology ADC Royalty Upside Potential
Halozyme Therapeutics (NasdaqGS:HALO) has entered a new global collaboration with GSK to apply its ENHANZE technology to subcutaneous delivery of multiple oncology products.
The agreement includes development of subcutaneous formulations for antibody drug conjugates, expanding ENHANZE into a new class of cancer therapies.
The collaboration introduces additional potential royalty streams tied to future use of ENHANZE across GSK’s oncology portfolio.
Halozyme Therapeutics, trading at $65.19,...